SCHEMBL566248

SCHEMBL566248

CCOP(OCCC#N)N(C(C)C)C(C)C

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383731 0.93 TSHR (0.32) TSHR
SCHEMBL4818972 0.91 TSHR (0.31) TSHR
SCHEMBL10030503 0.89 TSHR (0.35) TSHR
SCHEMBL10158968 0.88
SCHEMBL19325220 0.87
SCHEMBL12733567 0.86 TSHR (0.42) TSHR
SCHEMBL16504168 0.85 TSHR (0.30) TSHR
SCHEMBL2621446 0.85 TSHR (0.30) TSHR
SCHEMBL14136628 0.85 TSHR (0.30) TSHR
SCHEMBL15935503 0.85 TSHR (0.41) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230393157-A1 PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES CHIRON AS (NO) 2023-12-07 US disclosed
US-11827667-B2 Production method for guanosine derivative having fluorine atom-containing functional group at position 8 and application thereof UNIVERSITY OF MIYAZAKI (JP) 2023-11-28 US disclosed
US-20230332210-A1 REPORTER AND USE THEREOF SFC CO., LTD. (KR) 2023-10-19 US disclosed
US-20230332210-A1 REPORTER AND USE THEREOF SFC CO., LTD. (KR) 2023-10-19 US disclosed
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
WO-2023177808-A1 MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2023-09-21 WO disclosed
EP-4214216-A1 PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES Chiron AS (NO) 2023-07-26 EP disclosed
EP-3125946-B1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD (IL) 2022-12-07 EP disclosed
US-11318206-B2 Compounds and methods for trans-membrane delivery of molecules APOSENSE LTD (IL) 2022-05-03 US disclosed
WO-2022058192-A1 PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES CHIRON AS (NO) 2022-03-24 WO disclosed
US-9499572-B2 Phosphatidylalkanols and compositions thereof Pethmark AB (SE) 2016-11-22 US disclosed
US-20160052946-A1 NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF Pethmark AB (SE) 2016-02-25 US disclosed
US-20150203847-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS INC (US) 2015-07-23 US disclosed
US-8962580-B2 Chemical modifications of monomers and oligonucleotides with cycloaddition ALNYLAM PHARMACEUTICALS, INC. (US) 2015-02-24 US disclosed
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-09 US disclosed
US-7897736-B2 Fluorescent quenching detecting reagents and methods ELITECH HOLDING B.V. (NL) 2011-03-01 US disclosed
US-7855293-B2 Fluorescent dyes such as 2-(4-acetanilino-1,3-butadieneyl)-3-spiro-1'-cyclohexan-1-(4-sulfobutyl)-3H -indolium hydroxide metal salts which couple biological materials without loss of fluorescence due to self-quenching HAALCK LUTZ 2010-12-21 US disclosed
US-7855293-B2 Fluorescent dyes such as 2-(4-acetanilino-1,3-butadieneyl)-3-spiro-1'-cyclohexan-1-(4-sulfobutyl)-3H -indolium hydroxide metal salts which couple biological materials without loss of fluorescence due to self-quenching HAALCK LUTZ 2010-12-21 US disclosed
US-20100174058-A1 FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS ELITECHGROUP, INC. 2010-07-08 US disclosed
US-7662942-B2 Oligonucleotide probes containing two labels useful in hybridization assays Elitech Holdings, B.V. (NL) 2010-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203847-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION DNMT1, LCK, MCTS1 TSHR 3178/4885
US-20100174058-A1 FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS DDX5, DDX21, DCLRE1B TSHR 2990/4885
US-20160052946-A1 NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF PHOSPHO1, SGMS1, DEGS1 TSHR 1894/4885
US-20230393157-A1 PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES PHOSPHO1, SGMS2, SGMS1 TSHR 4269/4885
US-11827667-B2 Production method for guanosine derivative having fluorine atom-containing functional group at position 8 and application thereof RNMT, FBL, NOP2 TSHR 1340/4885
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators STING1, CGAS, IRF3 TSHR 4157/4885
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION DNMT1, LCK, MCTS1 TSHR 3178/4885
US-11318206-B2 Compounds and methods for trans-membrane delivery of molecules ABCB4, LNPK, MBOAT1 TSHR 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.